A Study to Find Out How Much Mirabegron Gets Into the Body After Dosing With a Tablet Formulation

Inclusion Criteria: * Body weight between 60.0 and 100.0 kg and Body Mass Index between 18.0 and 30.0 kg/m2 Exclusion Criteria: * Known or suspected hypersensitivity to β-adrenergic receptor agonists or constituents of the formulations used * Clinically significant elevation of serum creatinine or liver enzymes as evidenced by creatinine \>150 ųmol/L; ASAT, ALAT or LDH\> 2x ULN; ɣ-GT \> 3x ULN and/or abnormal serum bilirubin * Any clinically significant history of asthma, eczema, any other allergic condition or previous severe hypersensitivity to any drug * Subjects taking β blockers or β agonists (eye drops allowed) * Any clinically significant history of upper gastrointestinal symptoms (such as nausea, vomiting, abdominal discomfort or upset, or heartburn) in the 4 weeks prior to the first admission to the Research Unit * Any clinically significant history of any other disease or disorder - gastrointestinal, cardiovascular, respiratory, ophthalmologic, renal, hepatic, neurological, dermatological, psychiatric or metabolic * Any clinically significant abnormality following the investigator's review of the pre-study physical examination, ECG and clinical laboratory tests * QTcB interval of \> 430 (mean QTcB of two measurements \> 430msec) * Abnormal pulse rate measurement (\<40 or \>90 bpm) at the pre-study visit after subject has been resting in supine position for 5 min. * Abnormal blood pressure measurements taken at the pre-study visit after subject has been resting in supine position for 5 min as follows: * Systolic blood pressure \<95 or \>160 mmHg * Diastolic blood pressure \<40 or \>90 mmHg * Positive orthostatic test at screening i.e. any symptoms of dizziness, light-headedness etc. and a fall of \> 20 mmHg in systolic blood pressure after 2 min standing and an increase in pulse rate of ≥ 20 bpm * Regular use of any prescribed or OTC drugs except paracetamol up to 3 g/day, in the 4 weeks prior to admission to the Research Unit OR any use of such drugs in the 2 weeks prior to first admission to the Research Unit